Cybin Inc., a clinical-stage neuropsychiatry company, will participate in a Water Tower Research Fireside Chat on May 29, 2025. During the event, CEO Doug Drysdale will discuss the evolution of interventional psychiatry clinics, the importance of Cybin's partnership with Osmind, the progress of the CYB003 Phase 3 program, and the impact of strategic clinical partnerships and the Thermo Fisher collaboration. Upcoming milestones and the FDA's stance on psychedelics will also be covered.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cybin Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250522228359) on May 22, 2025, and is solely responsible for the information contained therein.